Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression

Wang, Yingyi; Zhou, Na; Liu, Hong‐sheng; Gong, Xiaolei; Zhu, Rui; Li, Xiaoyuan; Sun, Zhao; Zong, Xu‐Hong; Li, Ningning; Meng, Changting; Bai, Chunmei; Li, Tai‐Sheng

doi:10.1002/cam4.3150

Cited by 37 publications

(33 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The research suggested that ACL could be served as a potential peripheral blood immune impairment markers in patients with BC to monitor the immune function, and predict the prognosis and therapeutic effect. It is the rst time to report the clinic value of peripheral ACL in BC, though some research suggested that total number of peripheral blood lymphocytes was associated to the prognosis and therapeutic effect [13,14,15,29,30]. Firstly, just as our study showed, there was no signi cant difference in the percentages of CD3 + , CD3 + CD4 + , CD3 + CD8 + , B, and NK cells between NCs and BC patients.…”

Section: Discussionmentioning

confidence: 52%

“…Traditionally, the ACL was measured by dual-platform technology by which the percentages of lymphocyte subsets measured by ow cytometry was combined with the absolute lymphocyte count measured by an automatic hematology analyzer,which produced obvious errors among different laboratories [11][12][13][14]. Here, we adopted the single-platform technology to carry out the detection entirely on the ow cytometer, which signi cantly improved the accuracy of the analysis.…”

Section: Read Full License Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Absolute Counts of Peripheral Lymphocyte Subsets as Potential Immune Impairment Markers in Patients With Breast Cancer

Liu¹,

Xia²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose This study was to evaluate clinic value of absolute counts of lymphocyte subsets (ACL) as potential blood biomarkers in progression and prognosis in breast cancer (BC) patients.Methods A total of 237 BC patients and 55 age-matched female normal healthy donors (normal cantrals, NCs) were enrolled in this study. The absolute counts (AC) and percentages of CD3+, CD3+CD4+, CD3+CD8+, B and NK cells were determined by flow cytometry. The clinicopathological parameters influencing disease progression were determined by binary logistic regression. The progression-free survival (PFS) was evaluated by Kaplan-Meier. Univariable and multivariable analyses were performed using log-rank test and proportional hazard regression models, respectively.Results Compared with NCs, the ACL in BC patients decreased significantly, while the percentages of lymphocytes showed no change. Of them, AC of CD3+CD4+ cells was closely related to clinical stages. The ACL, especially CD3+CD4+ cells, were affected by different treatments. Analysis of logistic regression showed that the cut-off value of CD3+CD4+ cells ≥ 451 cells/μL was the favorable prognostic factor. Multivariate analysis of prognostic factors of PFS showed CD3+CD4+ and CD3+CD8+ cells were independent factors for predicting PFS.Conclusions The AC of CD3+, CD3+CD4+, CD3+CD8+, B, and NK cells in BC patients were impaired obviously and can be as potential susceptive indications to evaluate the patient's immune states. The higher level of AC of CD3+CD4+ and CD3+CD8+ cells contributed to longer PFS and favorable outcome, and could help to adopt appropriate treatment strategies in clinic.

show abstract

Section: Discussionmentioning

confidence: 52%

Section: Read Full License Introductionmentioning

confidence: 99%

Absolute Counts of Peripheral Lymphocyte Subsets as Potential Immune Impairment Markers in Patients With Breast Cancer

Liu¹,

Xia²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Numerous studies have indicated the prognostic value of peripheral blood lymphocyte subsets in cancer patients (36)(37)(38). However, the prognostic roles of peripheral blood lymphocyte subsets in NSCLC patients treated with ICIs is unclear.…”

Section: Discussionmentioning

confidence: 99%

A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors

Xu¹,

Wang²,

Chen³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: The primary aim of this study was to investigate the prognostic value of peripheral blood lymphocyte subsets in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).Methods: From 2018 to 2019, 82 patients diagnosed with stage IIIB-IV NSCLC at Zhejiang Cancer Hospital were recruited for this study. Peripheral blood lymphocyte subsets of NSCLC patients were analyzed using flow cytometry before and after ICI treatment. The relationship between the percentage of peripheral blood lymphocyte subsets, clinicopathological features, progression-free survival (PFS), and overall survival (OS) was identified by correlation heat map, Kaplan-Meier curve, log-rank test, and Cox regression analysis.Results: The CD4/CD8 ratio and the percentage of B cells was decreased after ICI treatment. Furthermore, the percentage of CD3 + T cells, natural killer (NK) cells, and natural killer T (NKT) cells before ICI treatment was associated with brain metastases, the proportion of CD3 + CD4 + T cells before ICI treatment was related to epidermal growth factor receptor (EGFR) status, the CD4/CD8 ratio before ICI treatment was correlated to pathology, the ratio of B cells before ICI treatment was related to therapeutic regimen, and the percentage of NKT cells before ICI treatment was associated with use of radiotherapy. Furthermore, univariate survival analysis revealed that low percentage of B cells forecasted a poor OS for NSCLC patients with ICI treatment. In addition, the nomogram developed by percentages of peripheral blood lymphocyte subsets could determine survival probability and survival time of NSCLC patients with immunotherapy.Conclusions: ICI treatment induced changes in the percentage of peripheral blood lymphocyte subsets, which had prognostic value for brain metastases, radiotherapy, EGFR status, pathology, and therapeutic regimen, along with prognostic value, for NSCLC patients treated with ICIs. 2 Xu et al. A nomogram model for the prognosis of NSCLC patients

show abstract

“…Lymphocytes play a crucial role in cancer development, either in anti-tumor immunity or pro-tumor immunity (18). Circulating lymphocyte subsets have been observed to be associated with the prognosis of several types of cancer (19)(20)(21), and to be affected by various treatments including chemotherapy (17,22). Some research has shown that compared to T cells, the number and function of B cells are more adversely affected by chemotherapy (23), and the alternations of immune function may last for a longer period than the treatment (17).…”

Section: Introductionmentioning

confidence: 99%

Changes of proportions of circulating lymphocyte subsets in cancer patients after chemotherapy

Wang¹,

Wang²,

Cao³

2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background It remains unknown how chemotherapy affects circulating lymphocyte subsets and whether the pattern of change is related to prognosis in cancer patients. Methods Cancer patients who received chemotherapy between 2018/03/01 and 2019/12/31 were enrolled from the Hefei Cancer Hospital, Chinese Academy of Sciences. Peripheral blood samples were collected before and 3 weeks after the start of chemotherapy, and the proportions of T cells (CD3+), helper T cells (CD3+CD4+), cytotoxic T cells (CD3+CD8+), B cells (CD19+), and Natural killer (NK) cells (CD3−CD56+) were examined by flow cytometry. Multivariable logistic regression analysis was employed to explore risk factors associated with overall survival within 12 months after the start of chemotherapy. Results A total of 167 patients with cancer were included in the analysis, including 14 cases of cervical cancer, 18 cases of breast cancer, 33 cases of gastric cancer, 48 cases of lung cancer, 21 cases of colorectal cancer, and 33 cases of esophageal cancer. The proportion of T cells (72.58%±10.44% vs. 80.67%±11.63%, P<0.001) and cytotoxic T cells (25.38%±8.87% vs. 39.20%±12.26%, P<0.001) significantly increased, while the proportion of helper T cells (45.58%±10.19% vs. 41.98%±10.47%, P<0.001), B cells (15.10%±5.23% vs. 11.29%±5.60%, P<0.001), and NK cells (19.33%±7.54% vs. 18.28%±7.62%, P<0.001) significantly decreased at 3 weeks after chemotherapy when compared to baseline levels. The overall mortality rate was 14.97% (25/167) within 1 year after the start of chemotherapy. Patients who survived showed a significantly less increase in cytotoxic T cells (13.38%±8.28% vs. 17.28%±7.97%, P=0.030) and less decrease in B cells (−3.58%±2.81% vs. −5.29%±3.03%, P=0.006) when compared to non-survivors. Greater decreases in helper T cells (OR 0.81, 95% CI, 0.68–0.96) and B cells (OR 0.72, 95% CI, 0.59–0.87), and a greater increase in cytotoxic T cells (OR 1.09, 95% CI, 1.03–1.16) were risk factors for poor overall survival. Conclusions Circulating lymphocyte subsets of cancer patients presented characteristic changes after chemotherapy. Patients with a greater decrease in helper T cells and B cells, or greater increase in cytotoxic T cells, may have worse survival.

show abstract

Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression

Cited by 37 publications

References 36 publications

Absolute Counts of Peripheral Lymphocyte Subsets as Potential Immune Impairment Markers in Patients With Breast Cancer

Absolute Counts of Peripheral Lymphocyte Subsets as Potential Immune Impairment Markers in Patients With Breast Cancer

A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors

Changes of proportions of circulating lymphocyte subsets in cancer patients after chemotherapy

Contact Info

Product

Resources

About